復宏漢霖(02696.HK)完成H藥斯魯利單抗首批海外發貨
復宏漢霖(02696.HK)宣布,H藥斯魯利單抗Zerpidio(漢斯狀)完成首批海外發貨,該批藥品由復宏漢霖松江基地(一)出貨,抵達浦東機場附近的發貨倉,終點站為印尼。
去年12月28日,公司就H藥在東盟十國的商業合作夥伴KGbio附屬公司PT Kalbio Global Medika收到藥品註冊批件,H藥獲得印尼食品藥品監督管理局(BPOM)批准用於治療廣泛期小細胞肺癌(ES-SCLC),成為首個於東南亞獲批上市的國產抗PD-1單抗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.